1. [The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome].
- Author
-
Millán Núñez-Cortés J, Montoya JP, Salas XP, Hernández Mijares A, Carey VJ, Hermans MP, Sacks FM, and Fruchart JC
- Subjects
- Acute Coronary Syndrome etiology, Aged, Aged, 80 and over, Atherosclerosis blood, Atherosclerosis drug therapy, Atherosclerosis etiology, Cardiovascular Diseases blood, Case-Control Studies, Cholesterol, HDL blood, Cholesterol, LDL blood, Dyslipidemias blood, Dyslipidemias drug therapy, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypertriglyceridemia blood, Hypertriglyceridemia complications, Hypertriglyceridemia drug therapy, International Cooperation, Male, Medical Records statistics & numerical data, Meta-Analysis as Topic, Middle Aged, Patient Selection, Recurrence, Retrospective Studies, Risk, Risk Assessment, Acute Coronary Syndrome blood, Cardiovascular Diseases epidemiology, Dyslipidemias complications, Lipids blood
- Abstract
The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010., (Copyright © 2010 SEEN. Published by Elsevier Espana. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF